Bring native bispecific therapeutics to patients
We strongly believe that bispecific and multispecific antibodies can only meet their full potential if they are well tolerated by the human body.
Taking advantage of the unique features of human antibody light chains, we have developed an approach to generate bispecific antibodies that fully retain the sequence and architecture of human antibodies. They are therefore ideally suited for therapeutic applications, in particular if prolonged administration to patients is required.
We are developing a pipeline of unique therapeutics, bringing them to patients in different indications with high medical need.
